Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Allory

Showing results (141-150 of 208) with videos related to

Pageof 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2014
MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression arrayLaurence Albiges, Justine Guegan, Audrey Le Formal, et al.
The French Journal of Urology|June 26, 2026
Guidelines of the Oncology Committee of the French Association of Urology (CCAFU) and the Infectious Diseases Committee of the French Association of Urology (CIAFU) for Intravesical Instillation of Mitomycin C, Epirubicin, and BCG in NMIBCPriscilla Leon, Thibaut Long Depaquit, François Audenet, et al.
British Journal of Cancer|February 16, 2019
TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancerFlorent Dufour, Linda Silina, Hélène Neyret-Kahn, et al.
Histopathology|July 27, 2019
Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinomaVeronika Weyerer, Rebecca Weisser, Evgeny A Moskalev, et al.
EMBO Molecular Medicine|October 22, 2013
An essential role for decorin in bladder cancer invasivenessMohamed El Behi, Sophie Krumeich, Catalina Lodillinsky, et al.
Oncoimmunology|May 10, 2019
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancerEdith Borcoman, Philippe De La Rochere, Wilfrid Richer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2022
Rational testing for gene fusion in colorectal cancer: MSI and RAS-BRAF wild-type metastatic colorectal cancer as target population for systematic screeningMatthieu Delaye, Sabrina Ibadioune, Catherine Julié, et al.
Bladder Cancer (Amsterdam, Netherlands)|September 26, 2022
CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and PrognosisAlexandra Masson-Lecomte, Pascale Maillé, Silvia Pineda, et al.
BJU International|July 16, 2016
Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinibBenoit Beuselinck, Johnny Jean-Baptiste, Patrick Schöffski, et al.
The Journal of Pathology|October 6, 2021
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancerNanor Sirab, Damien Drubay, Pascale Maillé, et al.
Pageof 21

Showing results (141-150 of 208) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2014
MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression arrayLaurence Albiges, Justine Guegan, Audrey Le Formal, et al.
The French Journal of Urology|June 26, 2026
Guidelines of the Oncology Committee of the French Association of Urology (CCAFU) and the Infectious Diseases Committee of the French Association of Urology (CIAFU) for Intravesical Instillation of Mitomycin C, Epirubicin, and BCG in NMIBCPriscilla Leon, Thibaut Long Depaquit, François Audenet, et al.
British Journal of Cancer|February 16, 2019
TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancerFlorent Dufour, Linda Silina, Hélène Neyret-Kahn, et al.
Histopathology|July 27, 2019
Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinomaVeronika Weyerer, Rebecca Weisser, Evgeny A Moskalev, et al.
EMBO Molecular Medicine|October 22, 2013
An essential role for decorin in bladder cancer invasivenessMohamed El Behi, Sophie Krumeich, Catalina Lodillinsky, et al.
Oncoimmunology|May 10, 2019
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancerEdith Borcoman, Philippe De La Rochere, Wilfrid Richer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2022
Rational testing for gene fusion in colorectal cancer: MSI and RAS-BRAF wild-type metastatic colorectal cancer as target population for systematic screeningMatthieu Delaye, Sabrina Ibadioune, Catherine Julié, et al.
Bladder Cancer (Amsterdam, Netherlands)|September 26, 2022
CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and PrognosisAlexandra Masson-Lecomte, Pascale Maillé, Silvia Pineda, et al.
BJU International|July 16, 2016
Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinibBenoit Beuselinck, Johnny Jean-Baptiste, Patrick Schöffski, et al.
The Journal of Pathology|October 6, 2021
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancerNanor Sirab, Damien Drubay, Pascale Maillé, et al.
Pageof 21